HUTCHMED Hosts Expert Call on Immune Thrombocytopenia Insights
![HUTCHMED Hosts Expert Call on Immune Thrombocytopenia Insights](https://investorshangout.com/images/blog/investors-hangout-newswire.jpg)
HUTCHMED to Host Expert Call on Immune Thrombocytopenia
HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a physician expert call with a professor and key opinion leader in immune thrombocytopenia (ITP), to discuss the treatment landscape of ITP via webcast on an upcoming date at 7:00 p.m. HKT.
Event Details
The event will be held in Chinese (Putonghua) and can be accessed via www.hutch-med.com/event. Investors interested in listening to a webcast should log on before the start time to download any software required. The transcript of the event, including an English translation, will be available shortly thereafter for approximately 90 days. This event is intended for investor audiences only.
About ESLIM-01 Trial
ESLIM-01 is a Phase III trial of HUTCHMED’s novel investigational drug candidate sovleplenib in patients with primary ITP. The trial met all its endpoints and results were published in a prominent medical journal and orally presented at the European Hematology Association Hybrid Congress. HUTCHMED has filed a New Drug Application for sovleplenib in recent months.
Understanding Immune Thrombocytopenia (ITP)
ITP is an autoimmune disorder characterized by the immunologic destruction of platelets and decreased platelet production. Patients with ITP are at increased risk of excessive bleeding and bruising. ITP is also associated with fatigue and impaired quality of life. The incidence of primary ITP in adults is 3.3/100,000 adults per year with an estimated prevalence of 9.5 per 100,000 adults. Based on this prevalence rate, around 110,000 patients are estimated to be living with primary ITP in major markets.
Sovleplenib’s Role in Treatment
Sovleplenib is a novel, selective inhibitor of Syk intended for once daily oral administration. Syk is a significant component in B-cell receptor and FcR signaling, making it a promising target for various B-cell lymphomas and autoimmune disorders. It is currently under clinical investigation by HUTCHMED, which retains all rights to sovleplenib worldwide.
Other Indications for Sovleplenib
In addition to its application in ITP, sovleplenib is also being studied for warm antibody autoimmune hemolytic anemia and indolent non-Hodgkin’s lymphoma.
About HUTCHMED
HUTCHMED is an innovative, commercial-stage, biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies for cancer and immunological diseases. The company employs approximately 5,000 personnel, with a sizable team in oncology/immunology. HUTCHMED consistently aims to bring its cancer drug candidates to patients worldwide, having made significant strides with its first three medicines now marketed in select regions.
Frequently Asked Questions
What is the purpose of the HUTCHMED expert call?
The expert call aims to discuss the treatment landscape of immune thrombocytopenia and provide insights on the company’s drug candidates.
What is sovleplenib?
Sovleplenib is a novel drug candidate being investigated for treating ITP and other autoimmune disorders, specifically targeting Syk.
Who can attend the webcast?
The webcast is intended for investor audiences and interested parties should log in prior to the start time.
What is the incidence of ITP?
The incidence of primary ITP is approximately 3.3 cases per 100,000 adults per year.
How can I learn more about HUTCHMED?
More information can be found by visiting the official website of HUTCHMED or through their communication channels.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/